Liver fibrosis: mechanistic concepts and therapeutic perspectives
N Roehlen, E Crouchet, TF Baumert - Cells, 2020 - mdpi.com
Liver fibrosis due to viral or metabolic chronic liver diseases is a major challenge of global
health. Correlating with liver disease progression, fibrosis is a key factor for liver disease …
health. Correlating with liver disease progression, fibrosis is a key factor for liver disease …
Novel therapeutic targets for cholestatic and fatty liver disease
M Trauner, CD Fuchs - Gut, 2022 - gut.bmj.com
Cholestatic and non-alcoholic fatty liver disease (NAFLD) share several key
pathophysiological mechanisms which can be targeted by novel therapeutic concepts that …
pathophysiological mechanisms which can be targeted by novel therapeutic concepts that …
EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis–2021 update
Non-invasive tests are increasingly being used to improve the diagnosis and
prognostication of chronic liver diseases across aetiologies. Herein, we provide the latest …
prognostication of chronic liver diseases across aetiologies. Herein, we provide the latest …
EASL Clinical Practice Guidelines on sclerosing cholangitis
O Chazouilleres, U Beuers, A Bergquist, TH Karlsen… - Journal of …, 2022 - Elsevier
Management of primary or secondary sclerosing cholangitis is challenging. These Clinical
Practice Guidelines have been developed to provide practical guidance on debated topics …
Practice Guidelines have been developed to provide practical guidance on debated topics …
AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma
Abbreviations: AASLD, American Association for the Study of Liver Diseases; AIH,
autoimmune hepatitis; ALP, alkaline phosphatase; ASIR, age standardized incidence rate; …
autoimmune hepatitis; ALP, alkaline phosphatase; ASIR, age standardized incidence rate; …
Lysyl oxidases: from enzyme activity to extracellular matrix cross-links
SD Vallet, S Ricard-Blum - Essays in biochemistry, 2019 - portlandpress.com
The lysyl oxidase family comprises five members in mammals, lysyl oxidase (LOX) and four
lysyl oxidase like proteins (LOXL1-4). They are copper amine oxidases with a highly …
lysyl oxidase like proteins (LOXL1-4). They are copper amine oxidases with a highly …
AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis
Chronic liver disease (CLD) leads to liver fibrosis; it is associated with approximately two
million annual deaths worldwide and is an enormous health burden.[1, 2] The majority of …
million annual deaths worldwide and is an enormous health burden.[1, 2] The majority of …
Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis
SA Harrison, MF Abdelmalek, S Caldwell, ML Shiffman… - Gastroenterology, 2018 - Elsevier
Background & Aims Lysyl oxidase-like 2 contributes to fibrogenesis by catalyzing cross-
linkage of collagen. We evaluated the safety and efficacy of simtuzumab, a monoclonal …
linkage of collagen. We evaluated the safety and efficacy of simtuzumab, a monoclonal …
AI-based automation of enrollment criteria and endpoint assessment in clinical trials in liver diseases
Clinical trials in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as
nonalcoholic steatohepatitis) require histologic scoring for assessment of inclusion criteria …
nonalcoholic steatohepatitis) require histologic scoring for assessment of inclusion criteria …
[PDF][PDF] Lysyl oxidase (LOX) family members: rationale and their potential as therapeutic targets for liver fibrosis
The cross‐linking of structural extracellular matrix (ECM) components, especially fibrillar
collagens and elastin, is strongly implicated in fibrosis progression and resistance to fibrosis …
collagens and elastin, is strongly implicated in fibrosis progression and resistance to fibrosis …